Literature DB >> 27173800

Identification of quinones as novel PIM1 kinase inhibitors.

Richard L Schroeder1, Navneet Goyal1, Melyssa Bratton2, Ian Townley2, Nancy A Pham1, Phan Tram1, Treasure Stone1, Jasmine Geathers1, Kathy Nguyen1, Jayalakshmi Sridhar3.   

Abstract

PIM1 is a proto-oncogene encoding the serine/threonine PIM1 kinase. PIM1 kinase plays important roles in regulating aspects of cell cycle progression, apoptosis resistance, and has been implicated in the development of such malignancies as prostate cancer and acute myeloid leukemia among others. Knockout of PIM1 kinase in mice has been shown to be non-lethal without any obvious phenotypic changes, making it an attractive therapeutic target. Our investigation of anthraquinones as kinase inhibitors revealed a series of quinone analogs showing high selectivity for inhibition of the PIM kinases. Molecular modeling studies were used to identify key interactions and binding poses of these compounds within the PIM1 binding pocket. Compounds 1, 4, 7 and 9 inhibited the growth of DU-145 prostate cancer cell lines with a potency of 8.21μM, 4.06μM, 3.21μM and 2.02μM.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Emodin; Pim1 kinase; Prostate cancer; Quinones; Selectivity profile

Mesh:

Substances:

Year:  2016        PMID: 27173800      PMCID: PMC4899092          DOI: 10.1016/j.bmcl.2016.04.079

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  41 in total

1.  The Protein Data Bank.

Authors:  H M Berman; J Westbrook; Z Feng; G Gilliland; T N Bhat; H Weissig; I N Shindyalov; P E Bourne
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

2.  Emodin, an anthraquinone derivative isolated from the rhizomes of Rheum palmatum, selectively inhibits the activity of casein kinase II as a competitive inhibitor.

Authors:  H Yim; Y H Lee; C H Lee; S K Lee
Journal:  Planta Med       Date:  1999-02       Impact factor: 3.352

3.  Hit to lead account of the discovery of a new class of inhibitors of Pim kinases and crystallographic studies revealing an unusual kinase binding mode.

Authors:  Kevin Qian; Lian Wang; Charles L Cywin; Bennett T Farmer; Eugene Hickey; Carol Homon; Scott Jakes; Mohammed A Kashem; George Lee; Scott Leonard; Jun Li; Ronald Magboo; Wang Mao; Edward Pack; Charlene Peng; Anthony Prokopowicz; Morgan Welzel; John Wolak; Tina Morwick
Journal:  J Med Chem       Date:  2009-04-09       Impact factor: 7.446

4.  Crystal structures of proto-oncogene kinase Pim1: a target of aberrant somatic hypermutations in diffuse large cell lymphoma.

Authors:  Abhinav Kumar; Valsan Mandiyan; Yoshihisa Suzuki; Chao Zhang; Julie Rice; James Tsai; Dean R Artis; Prabha Ibrahim; Ryan Bremer
Journal:  J Mol Biol       Date:  2005-04-22       Impact factor: 5.469

5.  Structural basis of constitutive activity and a unique nucleotide binding mode of human Pim-1 kinase.

Authors:  Kevin C Qian; Lian Wang; Eugene R Hickey; Joey Studts; Kevin Barringer; Charline Peng; Anthony Kronkaitis; Jun Li; Andre White; Sheenah Mische; Bennett Farmer
Journal:  J Biol Chem       Date:  2004-11-03       Impact factor: 5.157

6.  Interferon-alpha activates multiple STAT proteins and upregulates proliferation-associated IL-2Ralpha, c-myc, and pim-1 genes in human T cells.

Authors:  S Matikainen; T Sareneva; T Ronni; A Lehtonen; P J Koskinen; I Julkunen
Journal:  Blood       Date:  1999-03-15       Impact factor: 22.113

7.  Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases.

Authors:  Zuping Xia; Christian Knaak; Jian Ma; Zanna M Beharry; Campbell McInnes; Wenxue Wang; Andrew S Kraft; Charles D Smith
Journal:  J Med Chem       Date:  2009-01-08       Impact factor: 7.446

8.  Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes.

Authors:  Shannon M Mumenthaler; Patricia Y B Ng; Amanda Hodge; David Bearss; Gregory Berk; Sarath Kanekal; Sanjeev Redkar; Pietro Taverna; David B Agus; Anjali Jain
Journal:  Mol Cancer Ther       Date:  2009-10       Impact factor: 6.261

9.  Emodin has a cytotoxic activity against human multiple myeloma as a Janus-activated kinase 2 inhibitor.

Authors:  Akihiro Muto; Mayumi Hori; Yosuke Sasaki; Akari Saitoh; Iho Yasuda; Tadahito Maekawa; Tomoe Uchida; Keiko Asakura; Tomonori Nakazato; Toshio Kaneda; Masahiro Kizaki; Yasuo Ikeda; Tadashi Yoshida
Journal:  Mol Cancer Ther       Date:  2007-03       Impact factor: 6.261

10.  Proviral activation of the putative oncogene Pim-1 in MuLV induced T-cell lymphomas.

Authors:  G Selten; H T Cuypers; A Berns
Journal:  EMBO J       Date:  1985-07       Impact factor: 11.598

View more
  6 in total

Review 1.  PIM kinase inhibition: co-targeted therapeutic approaches in prostate cancer.

Authors:  Sabina Luszczak; Christopher Kumar; Vignesh Krishna Sathyadevan; Benjamin S Simpson; Kathy A Gately; Hayley C Whitaker; Susan Heavey
Journal:  Signal Transduct Target Ther       Date:  2020-01-31

Review 2.  PIM1/STAT3 axis: a potential co-targeted therapeutic approach in triple-negative breast cancer.

Authors:  Sutapa Mahata; Pranab K Sahoo; Ranita Pal; Sinjini Sarkar; Tanuma Mistry; Sushmita Ghosh; Vilas D Nasare
Journal:  Med Oncol       Date:  2022-05-15       Impact factor: 3.064

3.  Naphthoquinone as a New Chemical Scaffold for Leishmanicidal Inhibitors of Leishmania GSK-3.

Authors:  Victor Sebastián-Pérez; Paula Martínez de Iturrate; Montserrat Nácher-Vázquez; Luis Nóvoa; Concepción Pérez; Nuria E Campillo; Carmen Gil; Luis Rivas
Journal:  Biomedicines       Date:  2022-05-14

4.  Identification of New Mono/Dihydroxynaphthoquinone as Lead Agents That Inhibit the Growth of Refractive and Triple-Negative Breast Cancer Cell Lines.

Authors:  Richard Schroeder; Mary Sfondouris; Navneet Goyal; Rajesh Komati; Achira Weerathunga; Cory Gettridge; Cheryl L Klein Stevens; Frank E Jones; Jayalakshmi Sridhar
Journal:  ACS Omega       Date:  2019-06-19

Review 5.  PIM kinase inhibition: co-targeted therapeutic approaches in prostate cancer.

Authors:  Sabina Luszczak; Christopher Kumar; Vignesh Krishna Sathyadevan; Benjamin S Simpson; Kathy A Gately; Hayley C Whitaker; Susan Heavey
Journal:  Signal Transduct Target Ther       Date:  2020-01-31

6.  Structure-Based Virtual Screening and De Novo Design of PIM1 Inhibitors with Anticancer Activity from Natural Products.

Authors:  Hwangseo Park; Jinwon Jeon; Kewon Kim; Soyeon Choi; Sungwoo Hong
Journal:  Pharmaceuticals (Basel)       Date:  2021-03-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.